Prednisolone for COVID-19

This cross‐sectional study investigated nonconventional therapies for COVID‐19 in Trinidad, emphasizing the need for documentation supporting future pharmaceutical research. The survey, conducted from June 20 to July 19, 2022, garnered responses from 57 participants aged 18 and above, with 82.46% vaccinated. The majority (81%) utilized both conventional and nonconventional therapies, revealing insights for potential alternatives to traditional treatments. Conventional treatments, including antibiotics, Ivermectin, anti‐inflammatories, analgesics, bronchodilators, and cough/flu syrups, were frequently reported. Nonconventional therapies encompassed vitamins, minerals, supplements, and various plant and animal products. When participants used conventional therapies, either alone or in combination with nonconventional ones, 13.21% reported side effects. These included severe thirst, headache, nausea, drowsiness, and one case of weight gain. Conversely, those exclusively using nonconventional treatments reported no side effects. Encouragingly, nonconventional therapies demonstrated promising effects in managing COVID‐19, emphasizing the need for meticulous selection, research, and development of their bioactive compounds as potential alternatives to conventional therapies.

AbstractCorona virus 19 (Covid-19) has caused many problems in public health, economic, and even cultural and social fields since the beginning of the epidemic. However, in order to provide therapeutic solutions, many researches have been conducted and various omics data have been published. But there is still no early diagnosis method and comprehensive treatment solution. In this manuscript, by collecting important genes related to COVID-19 and using centrality and controllability analysis in PPI networks and signaling pathways related to the disease; hub and driver genes have been identified in the formation and progression of the disease. Next, by analyzing the expression data, the obtained genes have been evaluated. The results show that in addition to the significant difference in the expression of most of these genes, their expression correlation pattern is also different in the two groups of COVID-19 and control. Finally, based on the drug-gene interaction, drugs affecting the identified genes are presented in the form of a bipartite graph, which can be used as the potential drug combinations.

The active global SARS-CoV-2 pandemic caused more than 426 million cases and 5.8 million deaths worldwide. The development of completely new drugs for such a novel disease is a challenging, time intensive process. Despite researchers around the world working on this task, no effective treatments have been developed yet. This emphasizes the importance of drug repurposing, where treatments are found among existing drugs that are meant for different diseases. A common approach to this is based on \emph{knowledge graphs}, that condense relationships between entities like drugs, diseases and genes. Graph neural networks (GNNs) can then be used for the task at hand by predicting links in such knowledge graphs. Expanding on state-of-the-art GNN research, Doshi {\sl et al.} recently developed the \drcov \ model. We further extend their work using additional output interpretation strategies. The best aggregation strategy derives a top-100 ranking of 8,070 candidate drugs, 32 of which are currently being tested in COVID-19-related clinical trials. Moreover, we present an alternative application for the model, the generation of additional candidates based on a given pre-selection of drug candidates using collaborative filtering. In addition, we improved the implementation of the \drcov \ model by significantly shortening the inference and pre-processing time by exploiting data-parallelism. As drug repurposing is a task that requires high computation and memory resources, we further accelerate the post-processing phase using a new emerging hardware --- we propose a new approach to leverage the use of high-capacity Non-Volatile Memory for aggregate drug ranking.